Compare · LIVN vs MASI
LIVN vs MASI
Side-by-side comparison of LivaNova PLC (LIVN) and Masimo Corporation (MASI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LIVN and MASI operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MASI is the larger of the two at $9.31B, about 2.9x LIVN ($3.22B).
- Over the past year, LIVN is up 58.6% and MASI is up 11.0% - LIVN leads by 47.7 points.
- MASI has been more active in the news (4 items in the past 4 weeks vs 3 for LIVN).
- MASI has more recent analyst coverage (24 ratings vs 20 for LIVN).
- Company
- LivaNova PLC
- Masimo Corporation
- Price
- $58.65-0.43%
- $178.43-0.02%
- Market cap
- $3.22B
- $9.31B
- 1M return
- -7.68%
- +0.34%
- 1Y return
- +58.62%
- +10.96%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2007
- News (4w)
- 3
- 4
- Recent ratings
- 20
- 24
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Masimo Corporation
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. The company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. The company offers coronavirus-2019 response and telehealth solutions; connectivity devices; and nasal high flow ventilation and neuromodulation solutions. The company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, physician offices, long term care facilities, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. Incorporated in 1989, the company is headquartered in Irvine, California.
Latest LIVN
- SEC Form DEFA14A filed by LivaNova PLC
- SEC Form DEF 14A filed by LivaNova PLC
- Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea
- SEC Form 4 filed by Tezel Ahmet
- SEC Form 4 filed by Poletti Franco
- SEC Form 4 filed by Makatsaria Vladimir
- SEC Form 4 filed by Shvartsburg Alex
- SEC Form 4 filed by Bolton Stephanie
- SEC Form 4 filed by Kozmina Natalia
- MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value
Latest MASI
- Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study
- SEC Form DEFA14A filed by Masimo Corporation
- Masimo Corporation filed SEC Form 8-K: Other Events
- Telix Strengthens Board with Additional Director Appointments
- SEC Form DEFM14A filed by Masimo Corporation
- Amendment: SEC Form SCHEDULE 13G/A filed by Masimo Corporation
- Masimo downgraded by Raymond James
- SEC Form PREM14A filed by Masimo Corporation
- CEO Szyman Catherine M. covered exercise/tax liability with 1,069 shares and converted options into 2,101 shares, increasing direct ownership by 16% to 7,605 units (SEC Form 4)
- EVP & Chief Financial Officer Young Micah W converted options into 873 shares and covered exercise/tax liability with 471 shares, increasing direct ownership by 2% to 25,656 units (SEC Form 4)